The pharmaceutical industry is experiencing a important shift in glucose treatment with the arrival of GLP-1 transdermal devices. These groundbreaking methods offer a likely convenient choice to subcutaneous injections for individuals dealing with type 2 diabetes. By avoiding the requirement for